Novo Nordisk Deal Lets Hims & Hers Sell Wegovy and Ozempic Under $300 Monthly
Novo Nordisk will sell FDA-approved Wegovy and Ozempic injectables and the oral Wegovy pill through Hims & Hers’ U.S. telehealth platform at current prices. Hims will stop advertising compounded GLP-1 alternatives after Novo cut prices from about $1,000 to below $300 monthly, with 600,000 Wegovy pill prescriptions since launch.
1. Agreement to Distribute FDA-Approved Drugs
Novo Nordisk has licensed its FDA-approved injectables Wegovy and Ozempic, as well as the oral Wegovy pill, to be sold directly through Hims & Hers’ telehealth platform in the U.S. under existing consumer pricing.
2. Pricing Strategy and Prescription Volume
Novo Nordisk cut list prices from about $1,000 to under $300 per month on its websites, while Hims & Hers will maintain those rates, boosting affordable access after 600,000 Wegovy pill prescriptions since launch.
3. Settlement of Compounding Dispute
Under the pact, Hims & Hers will cease advertising compounded GLP-1 treatments, although providers may still prescribe them when clinically necessary, resolving legal friction over its $49 compounded alternative and ending the patent dispute.